Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus

NCT01652729 · Completed

Last updated 2026-05-28

This clinical trial compares the effects of a weekly injectable diabetes medication (exenatide) to a daily pill (sitagliptin) and a placebo in adults with type 2 diabetes to see how it impacts blood sugar levels over 28 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 365 people

Who can join Ages 18+ · all sexes

Timeline Started 2013-02 · est. completion 2014-04

Where 60 sites · United States

What this study is testing ClinicalTrials.gov NCT01652729 ↗

Description as written by the study sponsor.

To compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by sitagliptin or placebo administered once daily for 28 weeks in subjects with type 2 diabetes mellitus.

Treatments tested

Exenatide once weekly suspension Drug
Sitagliptin Drug
Placebo Drug

Placebo oral capsule once daily

Main thing measured	Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28
Sponsor	AstraZeneca
Conditions studied	Diabetes Type 2
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01652729 ↗